Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study to Provide Continued Access to Napabucasin
2019-004753-87Phase 2Completed
- Sponsor
- Sumitomo Pharma Oncology
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of napabucasin in pancreatic adenocarcinoma (PDAC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Sumitomo Pharma Oncology. Primary endpoint: Adverse events. Started Jan 2020; status: completed.
02
Drugs
napabucasin
03
Conditions
pancreatic adenocarcinoma (PDAC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2019-004753-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004753-87.